Capecitabine Plus Bevacizumab Versus Capecitabine in Maintenance Treatment for Untreated Characterised KRAS Exon 2 Wild-type Metastatic Colorectal Cancer: a Retrospective Analysis in Chinese Postmenopausal Women

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Specialty Gastroenterology

Date 2019 Jan 27

PMID 30683047

Citations 2

Authors

Jinsong Su

Jiajie Lai

Ruikun Yang

Bo Xu

Ying Zhu

Mingdong Zhao

Chen Yang

Guanzhao Liang

Affiliations

Soon will be listed here.

Abstract

Background: Capecitabine plus bevacizumab (CAP-B) maintenance treatment after 6 cycles of capecitabine, oxaliplatin, and bevacizumab (CAPOXB) has demonstrated clinical activity and failure to compromise quality of life in patients with metastatic colorectal cancer (MCC) in a previous phase 3 CAIRO3 study. The objective of this study is to evaluate the efficacy and safety of CAP-B versus CAP in maintenance treatment after 6-cycle CAPOXB induction therapy in Chinese postmenopausal women with untreated characterised KRAS exon 2 wild-type MCC.

Methods: During 2012-2016, prospectively maintained databases were reviewed to evaluate cohorts with untreated characterised KRAS exon 2 wild-type MCC and stable disease or better after 6-cycle CAPOXB induction treatment. After induction treatment, all patients received either CAP-B or capecitabine (CAP) as maintenance treatment. Median progression-free survival (mPFS) and median overall survival (mOS) were the primary endpoints. Safety was the secondary endpoint.

Results: A total of 263 women with untreated characterised KRAS exon 2 wild-type MCC and stable disease or better after 6-cycle CAPOXB induction treatment were included for the evaluation of efficacy and safety (CAP-B-treated cohort, n = 130 and CAP-treated cohort, n = 133). The mPFS was 11.5 months (95% confidence interval [CI], 5.6-17.4) and 9.2 months (95% CI, 3.6-14.8) for the CAP-B-treated and CAP-treated cohorts, respectively (HR 0.54, 95% CI 0.32~0.85; P = 0.013). The mOS was 16.2 months (95% CI, 11.4-18.7) and 12.4 months (95% CI, 10.6-15.5) for the CAP-B- and CAP-treated cohorts, respectively (HR 0.72, 95% CI 0.51~0.94; P = 0.022). The CAP-B-treated cohort experienced significantly more grade 3 or 4 diarrhoea (P < 0.001) than the CAP-treated cohort.

Conclusions: CAP-B maintenance treatment after 6-cycle CAPOX-B in Chinese postmenopausal women with untreated KRAS exon 2 wild-type MCC is poorer tolerated but has a more modest, if any, benefit compared with that of CAP maintenance treatment.

Citing Articles

Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS-mutant metastatic colorectal cancer.

Huang W, Zhang H, Tian Y, Cha Y, Xiong H, Yuan X J Clin Pharm Ther. 2022; 47(4):531-538.

PMID: 35218209 PMC: 9306912. DOI: 10.1111/jcpt.13576.

A novel cell-free single-molecule unique primer extension resequencing (cf-SUPER) technology for bladder cancer non-invasive detection in urine.

Zhao C, Pan Y, Wang Y, Li Y, Han W, Lu L Transl Androl Urol. 2020; 9(3):1222-1231.

PMID: 32676405 PMC: 7354286. DOI: 10.21037/tau-19-774.

References

Simi L, Pratesi N, Vignoli M, Sestini R, Cianchi F, Valanzano R . High-resolution melting analysis for rapid detection of KRAS, BRAF, and PIK3CA gene mutations in colorectal cancer. Am J Clin Pathol. 2008; 130(2):247-53. DOI: 10.1309/LWDY1AXHXUULNVHQ. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Allegra C, Jessup J, Somerfield M, Hamilton S, Hammond E, Hayes D . American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol. 2009; 27(12):2091-6. DOI: 10.1200/JCO.2009.21.9170. View

Feliu J, Safont M, Salud A, Losa F, Garcia-Giron C, Bosch C . Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer. Br J Cancer. 2010; 102(10):1468-73. PMC: 2869164. DOI: 10.1038/sj.bjc.6605663. View

Tebbutt N, Wilson K, Gebski V, Cummins M, Zannino D, Van Hazel G . Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol. 2010; 28(19):3191-8. DOI: 10.1200/JCO.2009.27.7723. View

Kang M, Hong Y, Kim K, Kim S, Baek J, Ryu M . Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. Invest New Drugs. 2011; 30(4):1607-13. DOI: 10.1007/s10637-011-9703-8. View

Konigsberg R, Hulla W, Klimpfinger M, Reiner-Concin A, Steininger T, Buchler W . Clinical and economic aspects of KRAS mutational status as predictor for epidermal growth factor receptor inhibitor therapy in metastatic colorectal cancer patients. Oncology. 2012; 81(5-6):359-64. DOI: 10.1159/000334919. View

Nakayama G, Uehara K, Ishigure K, Yokoyama H, Ishiyama A, Eguchi T . The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemother Pharmacol. 2012; 70(4):575-81. PMC: 3456942. DOI: 10.1007/s00280-012-1948-1. View

Rebersek M, Boc M, Cerkovnik P, Benedik J, Hlebanja Z, Volk N . Efficacy of first-line systemic treatment in correlation with BRAF V600E and different KRAS mutations in metastatic colorectal cancer - a single institution retrospective analysis. Radiol Oncol. 2012; 45(4):285-91. PMC: 3423757. DOI: 10.2478/v10019-011-0039-y. View

10.

Webster J, Kauffman T, Feigelson H, Pawloski P, Onitilo A, Potosky A . KRAS testing and epidermal growth factor receptor inhibitor treatment for colorectal cancer in community settings. Cancer Epidemiol Biomarkers Prev. 2012; 22(1):91-101. PMC: 3567775. DOI: 10.1158/1055-9965.EPI-12-0545. View

11.

Lang I, Brodowicz T, Ryvo L, Kahan Z, Greil R, Beslija S . Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial. Lancet Oncol. 2013; 14(2):125-33. DOI: 10.1016/S1470-2045(12)70566-1. View

12.

Cunningham D, Lang I, Marcuello E, Lorusso V, Ocvirk J, Shin D . Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol. 2013; 14(11):1077-1085. DOI: 10.1016/S1470-2045(13)70154-2. View

13.

Naeim A, Ward P, Wang H, Dichmann R, Liem A, Chan D . A phase II trial of frontline capecitabine and bevacizumab in poor performance status and/or elderly patients with metastatic colorectal cancer. J Geriatr Oncol. 2014; 4(4):302-9. DOI: 10.1016/j.jgo.2013.05.001. View

14.

Chen Y, Cao D, Bi F, Li Q, Qiu M . Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population. Med Oncol. 2014; 31(5):935. DOI: 10.1007/s12032-014-0935-2. View

15.

Cserepes M, Ostoros G, Lohinai Z, Raso E, Barbai T, Timar J . Subtype-specific KRAS mutations in advanced lung adenocarcinoma: a retrospective study of patients treated with platinum-based chemotherapy. Eur J Cancer. 2014; 50(10):1819-1828. DOI: 10.1016/j.ejca.2014.04.001. View

16.

Li W, Shi Q, Wang W, Liu J, Ren J, Li Q . KRAS status and resistance to epidermal growth factor receptor tyrosine-kinase inhibitor treatment in patients with metastatic colorectal cancer: a meta-analysis. Colorectal Dis. 2014; 16(11):O370-8. DOI: 10.1111/codi.12749. View

17.

Gligorov J, Doval D, Bines J, Alba E, Cortes P, Pierga J . Maintenance capecitabine and bevacizumab versus bevacizumab alone after initial first-line bevacizumab and docetaxel for patients with HER2-negative metastatic breast cancer (IMELDA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15(12):1351-60. DOI: 10.1016/S1470-2045(14)70444-9. View

18.

Cao R, Zhang S, Ma D, Hu L . A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med Oncol. 2014; 32(1):325. DOI: 10.1007/s12032-014-0325-9. View

19.

Price T, Bruhn M, Lee C, Hardingham J, Townsend A, Mann K . Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. Br J Cancer. 2015; 112(6):963-70. PMC: 4366893. DOI: 10.1038/bjc.2015.37. View

20.

Simkens L, van Tinteren H, May A, Ten Tije A, Creemers G, Loosveld O . Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet. 2015; 385(9980):1843-52. DOI: 10.1016/S0140-6736(14)62004-3. View